📄 Category

health economics

37 papers

Health Insurance Expenditure Structure for Type 2 Diabetes Treatment in Vietnam by Hospital Classification, 2018-2022: A Descriptive Analysis of Claims Data From Hanoi and Ho Chi Minh City

This descriptive analysis of Vietnamese health insurance claims from 2018 to 2022 reveals that total Type 2 diabetes treatment expenditures nearly doubled, with medication costs constituting the largest share and spending heavily concentrated in Class I and II hospitals, underscoring the need to strengthen care at lower-level facilities to improve resource allocation.

Nguyen, T. T. T., Nguyen, V. L., Vo, N. N. Y., Nguyen, H. C. D., Nguyen, H. T. T.2026-04-13📄 health economics

Designing national programs for expanded carrier screening: Results from a discrete-choice experiment in Singapore

This study in Singapore utilized a discrete-choice experiment to determine that a national expanded carrier screening program would achieve the highest uptake and public preference if it offers multiple screening options, minimizes costs and wait times, and expands eligibility beyond married couples.

Blythe, R., Senanayake, S., Bylstra, Y., Roberts, J., Choi, C., Yeo, M. J., Goh, J., Graves, N., Koh, A. L., Jamuar, S. S.2026-04-13📄 health economics

Neurogenic dysphagia as an independent driver of hospital length of stay and costs: a Bayesian analysis with geriatric stratification and intervention simulation

This Bayesian analysis of over 10,000 neurological inpatients demonstrates that neurogenic dysphagia is an independent driver of significantly increased hospital length of stay and costs, particularly in geriatric patients, and that simulated improvements in swallowing function offer a high probability of substantial cost savings.

Werner, C. J., Meyer, T., Pinho, J., Mall, B., Schulz, J. B., Schumann-Werner, B.2026-04-10📄 health economics

Economic value of resistance-guided gonorrhea treatment: cost-neutrality thresholds for resistance test pricing in the United States

This study uses a stochastic simulation model to demonstrate that resistance-guided gonorrhea treatment in the United States offers significant economic value across multiple dimensions, with cost-neutrality thresholds for diagnostic tests ranging from near zero to $145 depending on resistance prevalence and the inclusion of system-level costs like delayed resistance emergence and avoided drug development.

Nichols, B. E., Wonderly Trainor, B., Hampson, G., Grad, Y. H., Klausner, J. D.2026-04-07📄 health economics

Updated Health Opportunity Cost Estimates for 92 Low- and Middle-Income Countries: Implications for Global Health Financing and Donor Allocation

This paper presents updated marginal cost estimates per disability-adjusted life year (DALY) averted for 92 low- and middle-income countries using recent data and previously established elasticities, demonstrating that aligning domestic health spending with the Abuja Declaration and reallocating development assistance based on these opportunity costs could significantly maximize global health gains.

Ochalek, J. M.2026-04-02📄 health economics

Defining the potential impact and cost-effectiveness of a non-invasive diagnostic for malaria: a modeling study

This modeling study demonstrates that while universal non-invasive diagnostics (NIDs) maximize malaria case detection, a hybrid strategy combining NID screening with confirmatory rapid diagnostic tests offers the optimal balance of improved case finding, reduced antimicrobial overuse, and cost-effectiveness across diverse epidemiological settings.

Hansen, M. A., de Nooy, A., Calarco, S., Tetteh, K. K., Nichols, B. E.2026-04-01📄 health economics

Magnitude and Associated Factors of Out-of-Pocket Healthcare Expenditure among Outpatients Visiting Public Hospitals in Jigjiga Town, Somali Region, Eastern Ethiopia

This study reveals that out-of-pocket healthcare expenditure is highly prevalent among outpatients in Jigjiga, Ethiopia, with nearly 90% of patients incurring costs, and identifies female sex, unmarried status, higher education, and longer travel distances as significant predictors of these expenses.

Ahmed, M. M., Shitaye, D. D., Cheru, A., Weldesenbet, A. B., Negash, B.2026-03-30📄 health economics

Determining context-specific economically feasible age ranges for female HPV catch-up vaccination in LMICs: a model-based health economic assessment

This model-based assessment of 132 low- and middle-income countries demonstrates that expanding female HPV catch-up vaccination up to age 30 is highly impactful and cost-effective for cervical cancer elimination, though its budgetary feasibility varies significantly and relies heavily on sustainable financing and Gavi support.

Wondimu, A., Georges, D., Macacu, A., Wittenauer, R., Fuady, A., Gini, A., Baussano, I., Man, I.2026-03-27📄 health economics

The State of Health Visiting in England: Workforce Composition, Caseloads and Service Delivery

Utilizing new Freedom of Information data from 147 English Local Authorities, this study reveals that while health visiting spending remains progressive and mandated contact completion is stable across deprivation levels, the workforce has contracted and shifted toward lower-skilled staff with rising caseload pressures that disproportionately affect the most deprived areas, necessitating approximately 3,100 additional staff and £120 million annually to restore recommended service levels.

Conti, G., Weber Costa, G., D'Mello, D., Yu, Y.2026-03-27📄 health economics